← All trials
NCT04333732
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Feb 28, 2021
- First posted
- Apr 3, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 55000
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Washington University in St. LouisLead sponsor
- Washington University in St. LouisReponsible party - principal investigator
- Bill and Melinda Gates FoundationCollaborator
- Washington University in St. LouisOverall official - principal investigator
- Wits UniversityOverall official - principal investigator
- University of LondonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.